There was also an increase in the incidence of hypertension and dyspnea in the Kyprolis arm in comparison to Velcade in ENDEAVOR and than that observed in the ASPIRE research. Related StoriesNovo Nordisk announces FDA authorization of Tresiba for diabetes treatmentMylan sued in connection with ANDA filing for generic edition of ZytigaKolltan announces display of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015Structured on the Phase 3 ASPIRE study Amgen continues to utilize the FDA on the related sNDA in the U.S. And with the European Union regulatory authorities for the Marketing Authorization Application for Kyprolis.Based on previously reported pharmacokinetic outcomes, COL-003 is expected to provide adequate plasma concentrations to treat pain over a 12-hour period effectively. COL-003 is also made to resist common ways of tampering that typically defeat the time-release mechanism of typical formulations. The Company filed an IND application with the FDA for COL-172 in March of 2010 and the product is along the way to be moved into clinical advancement. These newly allowed claims continue steadily to broaden our overall intellectual property portfolio and strengthen our patent position in the region of novel extended-launch, tamper resistant formulations of opioids..